New drug combo targets advanced cancers in early trial
NCT ID NCT01445509
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 34 times
Summary
This early-phase study tested a combination of two drugs, dasatinib and bevacizumab, in 50 adults with advanced solid tumors that no longer responded to standard treatments. The goal was to find the safest doses and see how the drugs affected the cancer and the body. Participants took dasatinib daily by mouth and received bevacizumab as an IV infusion every two weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.